New drug classes for the treatment of partial onset epilepsy: focus on perampanel
Authors:
- Jerry ShihJSJerry Shih
- TatumTATatum
Open Access
- 1 July 2013
- journal article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 9, 285-93
Abstract
Peer reviewed article authored by (Shih JJ, Tatum WO, Rudzinski LA). Read article or submit your manuscript for publishing.Keywords
This publication has 32 references indexed in Scilit:
- Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromesEpilepsia, 2013
- Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)Epilepsy Research, 2013
- Perampanel—new promise for refractory epilepsy?Nature Reviews Neurology, 2012
- Randomized phase III study 306Neurology, 2012
- Revisiting AMPA Receptors as an Antiepileptic Drug TargetEpilepsy Currents, 2011
- Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)Epilepsy Research, 2010
- Rational polytherapyEpilepsia, 2009
- Development of new antiepileptic drugs: challenges, incentives, and recent advancesThe Lancet Neurology, 2007
- Lacosamide: A Review of Preclinical PropertiesCNS Drug Reviews, 2007
- Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy [RETIRED]Neurology, 2004